Clinical Trial Update: Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Bevacizumab to prevent acute respiratory distress syndrome in patients with severe sepsis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome
• Sepsis

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Severe Sepsis, Acute Respiratory Distress Syndrome | Phase 2 | Status: WITHDRAWN